Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.57 |
| ▸ | ADK | P55263 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 13/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 9/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22399452 | 0.91 | ADK (0.52) | PDE4DPDE3ASLC29A1ADKMETTL3 | |
| SCHEMBL15962778 | 0.89 | ADK (0.52) | PDE4DPDE3ASLC29A1ADKADORA2A | |
| SCHEMBL14644371 | 0.89 | ADK (0.52) | PDE4DPDE3ASLC29A1ADKADORA2A | |
| SCHEMBL18480770 | 0.89 | ADK (0.52) | PDE4DPDE3ASLC29A1ADKADORA2A | |
| SCHEMBL18470916 | 0.89 | ADK (0.52) | PDE4DPDE3ASLC29A1ADKADORA2A | |
| SCHEMBL14154291 | 0.89 | ADK (0.52) | PDE4DPDE3ASLC29A1ADKADORA2A | |
| SCHEMBL19229275 | 0.89 | ADK (0.52) | PDE4DPDE3ASLC29A1ADKADORA2A | |
| SCHEMBL19229329 | 0.89 | ADK (0.52) | PDE4DPDE3ASLC29A1ADKADORA2A | |
| SCHEMBL12150845 | 0.88 | ADK (0.56) | ADKADORA2AMETTL3PRMT5WDR77 | |
| SCHEMBL6841559 | 0.88 | ADK (0.56) | ADKADORA2AMETTL3PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132708-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF HUNTINGTON'S DISEASE | PROQR THERAPEUTICS II B.V. (NL) | 2025-06-26 | — | — | WO | claimed |
| WO-2025132708-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF HUNTINGTON'S DISEASE | PROQR THERAPEUTICS II B.V. (NL) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025104239-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CLASSIC GALACTOSEMIA | PROQR THERAPEUTICS II B.V. (NL) | 2025-05-22 | — | — | WO | disclosed |
| EP-3334745-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11453697-B1 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2022-09-27 | — | — | US | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10106574-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3334745-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017027646-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106574-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | PDE4D 65/4885PDE3A 186/4885SLC29A1 304/4885 |
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | PDE4D 65/4885PDE3A 186/4885SLC29A1 304/4885 |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | PDE4D 65/4885PDE3A 186/4885SLC29A1 304/4885 |
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | PDE4D 65/4885PDE3A 186/4885SLC29A1 304/4885 |
| US-11453697-B1 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | PDE4D 65/4885PDE3A 186/4885SLC29A1 304/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | PDE4D 65/4885PDE3A 186/4885SLC29A1 304/4885 |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | PDE4D 65/4885PDE3A 186/4885SLC29A1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.